| Primary information |
|---|
| ID | 12865 |
| Uniprot ID | P20366 |
| Description | Protachykinin-1 (PPT) [Cleaved into- Substance P; Neurokinin A (NKA) (Neuromedin L) (Substance K); Neuropeptide K (NPK); Neuropeptide gamma; C-terminal-flanking peptide] |
| Organism | Homo sapiens |
| Txonomy | Eukaryota; Opisthokonta; Metazoa; Eumetazoa; Bilateria; Deuterostomia; Chordata; Craniata; Vertebrata; Gnathostomata (jawed vertebrates); Teleostomi; Euteleostomi; Sarcopterygii; Dipnotetrapodomorpha; Tetrapoda; Amniota; Mammalia; Theria; Eutheria; Boreoeutheria; Euarchontoglires; Primates; Haplorrhini; Simiiformes; Catarrhini; Hominoidea (apes); Hominidae (great apes); Homininae; Homo; Homo sapiens (Human) |
| Subcellular Location | Secreted |
| Developmental Stage | NA |
| Similarity | Belongs to the tachykinin family. |
| Tissue Specificity | NA |
| Post Translational Modification | The substance P form is cleaved at Pro-59 by the prolyl endopeptidase FAP (seprase) activity (in vitro). |
| Function | Tachykinins are active peptides which excite neurons; evoke behavioral responses; are potent vasodilators and secretagogues; and contract (directly or indirectly) many smooth muscles. |
| Length | 129 |
| Molecular Weight | 15 |
| Name | Protachykinin-1 |
| Sequence | RPKPQQFFGLM |
| Sequence map | 264 |
| PDB ID | 3770210; 12853948; 12690205; 15489334; 1708336; 3038549; 9846828; 2284201; 21314817; 165036 |
| Drugpedia | 2B19;2KS9;2KSA;2KSB;4HOM; |
| Receptor | P25103; P21452; P29371; P25103; P21452; P21452; P29371; O14786; P25103 |
| Domain | NA |
| Pharmaceutical Use | NA
|